| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Bedinvetmab Basic information |
| Product Name: | Bedinvetmab | | Synonyms: | Bedinvetmab;Research Grade Bedinvetmab;Research Grade Bedinvetmab (DQB91701) | | CAS: | 2171034-69-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Bedinvetmab Structure]() |
| | Bedinvetmab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Bedinvetmab Usage And Synthesis |
| Uses | Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs[1][2]. | | in vivo | Bedinvetmab (0.5-1 mg/kg; s.c. for 28 d) alleviates the pain associated with canine osteoarthritis[1].
Bedinvetmab (1 mg/kg; s.c. monthly; 3× and 10× dose multiples) is well tolerated in normal laboratory Beagle dogs for 6 months and with 2 weeks' concurrent NSAID administration[2]. | | References | [1] Corral MJ, et, al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021 Nov;48(6):943-955. DOI:10.1016/j.vaa.2021.08.001
[2] Krautmann M, et, al. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021 Oct;276:105733. DOI:10.1016/j.tvjl.2021.105733 |
| | Bedinvetmab Preparation Products And Raw materials |
|